Considerations of Sex and Gender in FDA Tobacco Regulation

Danielle R. Davis; Suchitra Krishnan‐Sarin; Carolyn M. Mazure

doi:10.1001/jama.2023.6803

May 26, 2023JAMAOpen Access

Considerations of Sex and Gender in FDA Tobacco Regulation

View Full Paper

Ask AI

Bookmark

Share

Key Points

Assess how tobacco products differentially impact distinct sex and gender subpopulations to guide clinically meaningful regulatory policies.
Narrative policy analysis examining current Food and Drug Administration (FDA) tobacco regulatory practices.
Evaluation of clinical and public health evidence addressing sex- and gender-specific vulnerabilities to tobacco use.
Tobacco products produce distinct physiological, behavioral, and clinical consequences across sex and gender groups.
Standard regulatory strategies fail to address subpopulation disparities, demonstrating a critical need for targeted, evidence-based rulemaking.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Expert viewpoint discusses differential impacts of tobacco products across sex and gender subpopulations, highlighting the need for clinically meaningful FDA regulations.

Abstract

This Viewpoint discusses how sex and gender subpopulations may be differentially affected by tobacco products and suggests that the FDA formulate regulations in clinically meaningful ways.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davis et al. (2023) studied this question.

synapsesocial.com/papers/69d6b5def174babf6cab3415 https://doi.org/10.1001/jama.2023.6803

View Full Paper

Ask AI

Bookmark

Share

Considerations of Sex and Gender in FDA Tobacco Regulation

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Considerations of Sex and Gender in FDA Tobacco Regulation

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading